NO20053310L - Fremgangsmate og sammensetning til a behandle engstelse. - Google Patents

Fremgangsmate og sammensetning til a behandle engstelse.

Info

Publication number
NO20053310L
NO20053310L NO20053310A NO20053310A NO20053310L NO 20053310 L NO20053310 L NO 20053310L NO 20053310 A NO20053310 A NO 20053310A NO 20053310 A NO20053310 A NO 20053310A NO 20053310 L NO20053310 L NO 20053310L
Authority
NO
Norway
Prior art keywords
active ingredient
patient
pyridinyl
administered
treating anxiety
Prior art date
Application number
NO20053310A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053310D0 (no
Inventor
Janet Codd
Bernard Beer
Original Assignee
Nascime Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nascime Ltd filed Critical Nascime Ltd
Publication of NO20053310D0 publication Critical patent/NO20053310D0/no
Publication of NO20053310L publication Critical patent/NO20053310L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20053310A 2002-12-04 2005-07-04 Fremgangsmate og sammensetning til a behandle engstelse. NO20053310L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43074002P 2002-12-04 2002-12-04
PCT/US2003/037714 WO2004050019A2 (en) 2002-12-04 2003-11-25 Method and compositions for treating anxiety

Publications (2)

Publication Number Publication Date
NO20053310D0 NO20053310D0 (no) 2005-07-04
NO20053310L true NO20053310L (no) 2005-08-29

Family

ID=32469522

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053310A NO20053310L (no) 2002-12-04 2005-07-04 Fremgangsmate og sammensetning til a behandle engstelse.

Country Status (12)

Country Link
US (1) US20040192706A1 (pl)
EP (1) EP1581230A2 (pl)
JP (1) JP2006509789A (pl)
KR (1) KR20050085386A (pl)
CN (1) CN1720048A (pl)
AU (1) AU2003297559A1 (pl)
BR (1) BR0316192A (pl)
CA (1) CA2507609A1 (pl)
NO (1) NO20053310L (pl)
PL (1) PL377357A1 (pl)
RU (1) RU2005120749A (pl)
WO (1) WO2004050019A2 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154339A2 (en) * 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521422A (en) * 1983-06-23 1985-06-04 American Cyanamid Company Aryl and heteroaryl[7-(aryl and heteroaryl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US4626538A (en) * 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US6399621B1 (en) * 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration

Also Published As

Publication number Publication date
NO20053310D0 (no) 2005-07-04
JP2006509789A (ja) 2006-03-23
BR0316192A (pt) 2005-10-11
WO2004050019A9 (en) 2012-03-22
US20040192706A1 (en) 2004-09-30
PL377357A1 (pl) 2006-02-06
AU2003297559A1 (en) 2004-06-23
WO2004050019A3 (en) 2004-08-12
RU2005120749A (ru) 2006-01-20
WO2004050019A2 (en) 2004-06-17
KR20050085386A (ko) 2005-08-29
CA2507609A1 (en) 2004-06-17
EP1581230A2 (en) 2005-10-05
CN1720048A (zh) 2006-01-11

Similar Documents

Publication Publication Date Title
RU2130776C1 (ru) Пиразолпиримидиноны для лечения импотенции
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
SE0201669D0 (sv) New formulation and use thereof
WO2003045437A8 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
NO20004931L (no) Anvendelse av dexmedetomidin til sedering pÕ intensivavdeling
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
IL148057A (en) Use of cgrp antagonists for preparing a pharmaceutical composition for treating menopausal hot flashes
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MD523G2 (ro) Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
WO2007048220A3 (en) Trazodone composition for once a day adminisitiation
AU2002366567B2 (en) Use of an H1 antagonist and a safe steroid to treat rhinitis
AU2003229724B2 (en) Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
WO2004096118B1 (en) Composition for improving cognition and memory
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EP3345603B1 (en) Iloperidone metabolite for use in the treatment of psychiatric disorders
MX2025006204A (es) Tratamientos contra sindrome de cushing sin afectacion considerable de ritmos cardiacos
EE200200695A (et) (-)-5-(3-klorofenüül)-alfa-(4-klorofenüül)-alfa-(1-metüül-1H-imidasool-5-üül)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
WO2002056867A3 (en) Extended release pharmaceutical compositions containing beta-lactam antibiotics
MX2022015804A (es) Agente profilactico o terapeutico para porfiria.
JP2004520279A (ja) 早発射精の治療
JP5271188B2 (ja) 炎症治療薬の調製のためのミゾラスチンの使用
WO2004050019A9 (en) Method and compositions for treating anxiety